𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

✍ Scribed by A. R. Clamp; P. Schöffski; J. W. Valle; R. H. Wilson; S. Marreaud; A.-S. Govaerts; M. Debois; D. Lacombe; C. Twelves; J. Chick; G. C. Jayson; on behalf of the EORTC New Drug Development Group

Publisher
Springer
Year
2007
Tongue
English
Weight
315 KB
Volume
61
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of a l
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
✍ Francis J. Giles; Martin S. Tallman; Guillermo Garcia-Manero; Jorge E. Cortes; D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Abstract ## BACKGROUND OSI‐211 is a low‐clearance, unilamellar liposomal formulation of a water‐soluble camptothecin analogue, lurtotecan. OSI‐211 has significant activity in severe combined immunodeficient mouse models of human leukemia. ## METHODS This study was conducted to define the dose